NCT01825759 is a Phase 4 clinical trial of danshen dripping pill in Coronary Heart Disease, sponsored by West China Hospital.

Who is sponsoring NCT01825759?

NCT01825759 is sponsored by West China Hospital.

What drugs are being tested in NCT01825759?

Interventions in NCT01825759: danshen dripping pill.

What condition does NCT01825759 study?

NCT01825759 studies Coronary Heart Disease, Essential Hypertension.

Is NCT01825759 still recruiting?

NCT01825759 is currently status unknown. Last updated 5 April 2013.

Last reviewed 2013-04-05 · How we verify

NCT01825759

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function

Status unknown Phase 4 Last updated 5 April 2013

What this trial tests

Phase 4 trial testing danshen dripping pill in Coronary Heart Disease in 200 participants. Status unknown.

Timeline

1 January 2013

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 January 2013
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across China

Drugs / interventions tested

danshen dripping pill — full drug profile →

Conditions studied

Coronary Heart Disease — all drugs for Coronary Heart Disease →
Essential Hypertension — all drugs for Essential Hypertension →

Sponsor

West China Hospital

Who can join

Adults 35 to 75, any sex, with Coronary Heart Disease or Essential Hypertension. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pulse wave velocity
Time frame: one year

Sponsor's own description

The Impact of Compound danshen dropping pill for coronary heart disease (CHD) heart and artery structure and function in patients with hypertension

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs.
Habtemariam S. · · 2018 · cited 69× · PMID 29401682 · DOI 10.3390/ijms19020458
Cardiovascular Benefits of <i>Salvia miltiorrhiza</i> (Danshen) Supplementation: Bioactive Constituents, Mechanisms, Clinical Evidence and Implications for Nutritional Care.
Vikal A, Maurya R, Patel P, Kurmi BD, et al · · 2026 · PMID 42052427 · DOI 10.1002/fsn3.71755

Verify or expand the search:

Other recruiting trials for Coronary Heart Disease

Currently open trials in the same condition.

NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01825759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 5 April 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01825759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing